CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Sutro Biopharma, Inc. - STRO CFD

3.35
0.6%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.06
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Sutro Biopharma Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 3.33
Open* 3.26
1-Year Change* -38.61%
Day's Range* 3.26 - 3.35
52 wk Range 3.99-8.72
Average Volume (10 days) 372.48K
Average Volume (3 months) 8.77M
Market Cap 274.79M
P/E Ratio -100.00K
Shares Outstanding 60.53M
Revenue 56.87M
EPS -2.47
Dividend (Yield %) N/A
Beta 0.86
Next Earnings Date Nov 6, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 27, 2023 3.33 0.19 6.05% 3.14 3.40 3.14
Sep 26, 2023 3.27 0.06 1.87% 3.21 3.41 3.21
Sep 25, 2023 3.31 0.04 1.22% 3.27 3.33 3.16
Sep 22, 2023 3.27 -0.06 -1.80% 3.33 3.37 3.22
Sep 21, 2023 3.36 -0.09 -2.61% 3.45 3.45 3.34
Sep 20, 2023 3.53 -0.07 -1.94% 3.60 3.69 3.42
Sep 19, 2023 3.71 0.07 1.92% 3.64 3.80 3.64
Sep 18, 2023 3.75 -0.09 -2.34% 3.84 3.84 3.65
Sep 15, 2023 3.88 -0.20 -4.90% 4.08 4.17 3.82
Sep 14, 2023 4.19 -0.31 -6.89% 4.50 4.62 4.16
Sep 13, 2023 4.61 0.18 4.06% 4.43 4.63 4.43
Sep 12, 2023 4.52 0.01 0.22% 4.51 4.65 4.42
Sep 11, 2023 4.58 0.27 6.26% 4.31 4.63 4.26
Sep 8, 2023 4.49 -0.01 -0.22% 4.50 4.55 4.43
Sep 7, 2023 4.52 0.16 3.67% 4.36 4.56 4.33
Sep 6, 2023 4.49 0.33 7.93% 4.16 4.50 4.16
Sep 5, 2023 4.38 0.09 2.10% 4.29 4.53 4.23
Sep 1, 2023 4.48 -0.14 -3.03% 4.62 4.80 4.33
Aug 31, 2023 4.72 0.11 2.39% 4.61 4.93 4.61
Aug 30, 2023 4.82 0.15 3.21% 4.67 4.84 4.62

Sutro Biopharma, Inc. Events

Time (UTC) Country Event
Monday, November 6, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 Sutro Biopharma Inc Earnings Release
Q3 2023 Sutro Biopharma Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 67.772 61.88 42.722 42.736 38.419
Revenue 67.772 61.88 42.722 42.736 38.419
Total Operating Expense 196.715 160.404 113.779 98.204 75.642
Selling/General/Admin. Expenses, Total 59.544 56.004 36.818 32.592 21.38
Research & Development 137.171 104.4 76.961 65.612 54.262
Operating Income -128.943 -98.524 -71.057 -55.468 -37.223
Interest Income (Expense), Net Non-Operating 12.239 -7.014 38.929 -0.276 -0.007
Other, Net 1.913
Net Income Before Taxes -116.704 -105.538 -32.128 -55.744 -35.317
Net Income After Taxes -119.204 -105.538 -32.128 -55.744 -35.317
Net Income Before Extra. Items -119.204 -105.538 -32.128 -55.744 -35.317
Net Income -119.204 -105.538 -32.128 -55.744 -35.317
Income Available to Common Excl. Extra. Items -119.204 -105.538 -32.128 -55.744 -35.317
Income Available to Common Incl. Extra. Items -119.204 -105.538 -32.128 -55.744 -35.317
Diluted Net Income -119.204 -105.538 -32.128 -55.744 -35.317
Diluted Weighted Average Shares 50.7392 46.1191 32.5735 22.9586 22.8482
Diluted EPS Excluding Extraordinary Items -2.34935 -2.28838 -0.98632 -2.42803 -1.54572
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -2.34935 -2.28838 -0.98632 -2.42803 -1.54572
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 10.412 12.674 8.632 25.147 28.096
Revenue 10.412 12.674 8.632 25.147 28.096
Total Operating Expense 56.591 54.911 57.854 46.357 47.475
Selling/General/Admin. Expenses, Total 14.999 15.512 14.719 14.643 15.143
Research & Development 41.592 39.399 43.135 31.714 32.332
Operating Income -46.179 -42.237 -49.222 -21.21 -19.379
Interest Income (Expense), Net Non-Operating 8.248 -7.418 14.628 1.722 -4.133
Net Income Before Taxes -38.373 -49.655 -34.594 -19.488 -23.512
Net Income After Taxes -38.524 -50.05 -34.594 -19.488 -26.012
Net Income Before Extra. Items -38.524 -50.05 -34.594 -19.488 -26.012
Net Income -38.524 -50.05 -34.594 -19.488 -26.012
Income Available to Common Excl. Extra. Items -38.524 -50.05 -34.594 -19.488 -26.012
Income Available to Common Incl. Extra. Items -38.524 -50.05 -34.594 -19.488 -26.012
Diluted Net Income -38.524 -50.05 -34.594 -19.488 -26.012
Diluted Weighted Average Shares 60.3395 58.7234 57.09 52.3457 46.9572
Diluted EPS Excluding Extraordinary Items -0.63845 -0.8523 -0.60596 -0.37229 -0.55395
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.63845 -0.8523 -0.60596 -0.37229 -0.55395
Other, Net -0.442
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 353.153 218.515 378.182 128.568 209.946
Cash and Short Term Investments 334.364 197.938 368.137 117.864 204.492
Cash & Equivalents 47.254 30.414 206.152 4.96 125.298
Short Term Investments 287.11 167.524 161.985 112.904 79.194
Total Receivables, Net 7.122 12.454 5.559 6.298 2.489
Accounts Receivable - Trade, Net 7.122 12.454 5.559 6.298 2.489
Prepaid Expenses 11.667 8.123 4.486 4.406 2.965
Total Assets 406.944 341.408 394.111 156.37 223.139
Property/Plant/Equipment, Total - Net 51.064 51.591 12.935 9.633 10.934
Property/Plant/Equipment, Total - Gross 88.969 85.017 49.762 43.481 40.23
Accumulated Depreciation, Total -37.905 -33.426 -36.827 -33.848 -29.296
Other Long Term Assets, Total 2.727 2.527 2.994 2.56 2.259
Total Current Liabilities 66.547 41.736 29.597 32.967 36.423
Accounts Payable 4.797 11.327 5.544 5.584 3.061
Accrued Expenses 32.491 12.454 8.823 6.017 6.217
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 12.5 9.375 0 1 4.724
Other Current Liabilities, Total 16.759 8.58 15.23 20.366 22.421
Total Liabilities 189.896 88.844 62.063 58.581 91.6
Total Long Term Debt 3.771 15.738 24.545 8.876 10
Long Term Debt 3.771 15.738 24.545 8.876 10
Other Liabilities, Total 119.578 31.37 7.921 16.738 45.177
Total Equity 217.048 252.564 332.048 97.789 131.539
Redeemable Preferred Stock 0 0
Common Stock 0.058 0.046 0.046 0.023 0.023
Additional Paid-In Capital 670.223 586.243 559.746 293.346 281.891
Retained Earnings (Accumulated Deficit) -452.615 -333.411 -227.873 -195.745 -150.328
Other Equity, Total -0.618 -0.314 0.129 0.165 -0.047
Total Liabilities & Shareholders’ Equity 406.944 341.408 394.111 156.37 223.139
Total Common Shares Outstanding 57.4995 46.3812 45.7521 23.099 22.8482
Long Term Investments 0 68.775 0 15.609
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 304.063 353.153 346.553 331.511 228.742
Cash and Short Term Investments 276.494 334.364 324.248 225.636 209.145
Cash & Equivalents 62.472 47.254 96.779 79.115 28.901
Short Term Investments 214.022 287.11 227.469 146.521 180.244
Total Receivables, Net 9.873 7.122 11.241 97.671 11.686
Accounts Receivable - Trade, Net 9.873 7.122 11.241 97.671 11.686
Prepaid Expenses 17.696 11.667 11.064 8.204 7.911
Total Assets 358.016 406.944 400.7 385.62 303.675
Property/Plant/Equipment, Total - Net 49.831 51.064 51.354 51.316 51.657
Long Term Investments 0 0 0 20.699
Other Long Term Assets, Total 4.122 2.727 2.793 2.793 2.577
Total Current Liabilities 59.486 66.547 58.288 44.572 38.76
Accounts Payable 5.058 4.797 12.443 12.567 10.705
Accrued Expenses 24 32.491 13.011 8.868 6.486
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 17.186 16.759 20.334 10.637 9.069
Total Liabilities 172.603 189.896 170.974 176.562 83.303
Total Long Term Debt 0 3.771 6.783 9.779 12.762
Long Term Debt 0 3.771 6.783 9.779 12.762
Other Liabilities, Total 113.117 119.578 105.903 122.211 31.781
Total Equity 185.413 217.048 229.726 209.058 220.372
Common Stock 0.06 0.058 0.055 0.049 0.047
Additional Paid-In Capital 688.125 670.223 649.028 608.898 593.998
Retained Earnings (Accumulated Deficit) -502.665 -452.615 -418.021 -398.533 -372.521
Total Liabilities & Shareholders’ Equity 358.016 406.944 400.7 385.62 303.675
Total Common Shares Outstanding 60.1618 57.4995 54.6314 48.6742 46.3271
Current Port. of LT Debt/Capital Leases 13.242 12.5 12.5 12.5 12.5
Other Equity, Total -0.107 -0.618 -1.336 -1.356 -1.152
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -119.204 -105.538 -32.128 -55.744 -35.317
Cash From Operating Activities 3.549 -81.679 -67.802 -65.023 12.683
Cash From Operating Activities 5.69 4.844 4.297 4.777 4.539
Non-Cash Items 12.658 36.635 -28.485 9.208 0.855
Cash Interest Paid 1.869 2.046 1.675 1.049 1.275
Changes in Working Capital 104.405 -17.62 -11.486 -23.264 42.606
Cash From Investing Activities -35.022 -97.315 0.604 -51.131 -80.19
Capital Expenditures -7.858 -15.323 -7.129 -3.481 -1.557
Other Investing Cash Flow Items, Total -27.164 -81.992 7.733 -47.65 -78.633
Cash From Financing Activities 48.313 3.256 269.247 -4.184 170.785
Financing Cash Flow Items -0.463 0.778 -0.314 0.636 1.208
Issuance (Retirement) of Stock, Net 58.151 2.478 254.561 0.18 169.577
Net Change in Cash 16.84 -175.738 202.049 -120.338 103.278
Issuance (Retirement) of Debt, Net -9.375 0 15 -5
Cash Taxes Paid 0 0.103
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -50.05 -119.204 -84.61 -65.122 -39.11
Cash From Operating Activities -60.991 3.549 27.413 -38.441 -35.255
Cash From Operating Activities 1.615 5.69 4.162 2.724 1.327
Non-Cash Items 11.855 12.658 23.021 19.094 7.751
Cash Interest Paid 0.00039 1.869 1.442 0.998 0.504
Changes in Working Capital -24.411 104.405 84.84 4.863 -5.223
Cash From Investing Activities 67.451 -35.022 2.86 80.897 32.982
Capital Expenditures -0.942 -7.858 -4.491 -3.753 -1.553
Other Investing Cash Flow Items, Total 68.393 -27.164 7.351 84.65 34.535
Cash From Financing Activities 8.758 48.313 36.092 6.245 0.76
Financing Cash Flow Items -0.451 -0.463 -0.463 -0.413 -0.426
Issuance (Retirement) of Stock, Net 12.334 58.151 42.805 9.783 1.186
Issuance (Retirement) of Debt, Net -3.125 -9.375 -6.25 -3.125 0
Net Change in Cash 15.218 16.84 66.365 48.701 -1.513
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Suvretta Capital Management, LLC Hedge Fund 9.7208 5883693 194607 2023-06-30 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 7.7021 4661830 734685 2023-06-30 LOW
Rubric Capital Management LP Hedge Fund 6.6891 4048744 -311743 2023-06-30 MED
BVF Partners L.P. Hedge Fund 5.5313 3347946 0 2023-06-30 LOW
Franklin Advisers, Inc. Investment Advisor/Hedge Fund 4.6992 2844281 28704 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.6754 2829908 52946 2023-06-30 LOW
Holocene Advisors, LP Hedge Fund 3.5238 2132873 0 2023-06-30 HIGH
Verition Fund Management LLC Hedge Fund 3.2162 1946660 800874 2023-06-30 HIGH
Baillie Gifford & Co. Investment Advisor 3.0857 1867654 0 2023-06-30 LOW
Samsara BioCapital, LLC Venture Capital 2.7683 1675579 0 2023-06-30 LOW
Candriam Belgium S.A. Investment Advisor/Hedge Fund 2.6901 1628234 -232541 2023-06-30 MED
Candriam Luxembourg S.A. Investment Advisor 2.69 1628181 0 2023-06-30 MED
Millennium Management LLC Hedge Fund 2.4842 1503594 611978 2023-06-30 HIGH
Kynam Capital Management LP Hedge Fund 2.4782 1500000 598164 2023-06-30 HIGH
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 2.0021 1211788 38589 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.919 1161532 105218 2023-06-30 LOW
Parkman Healthcare Partners LLC Hedge Fund 1.8898 1143861 43823 2023-06-30 HIGH
State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.8077 1094121 -1828591 2023-06-30 LOW
Goldman Sachs Asset Management, L.P. Investment Advisor 1.6249 983488 -100529 2023-06-30 LOW
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 1.3336 807207 4056 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Sutro Biopharma, Inc. Company profile

About Sutro Biopharma Inc

Sutro Biopharma, Inc. is a clinical stage drug discovery, development, and manufacturing company. It is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. It is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Sutro Biopharma Inc revenues increased 45% to $61.9M. Net loss increased from $32.1M to $105.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Unrealized (loss) gain on equity securit decrease from $41.5M (income) to $4.5M (expense), Research and development increase of 31% to $97.3M (expense).

Industry: Bio Therapeutic Drugs

111 Oyster Point Blvd.
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

Oil - Crude

92.19 Price
-0.920% 1D Chg, %
Long position overnight fee 0.0590%
Short position overnight fee -0.0809%
Overnight fee time 21:00 (UTC)
Spread 0.030

XRP/USD

0.51 Price
-0.360% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

BTC/USD

26,544.70 Price
+0.950% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

ETH/USD

1,627.02 Price
+1.840% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading